ABSTRACT
Advances in the treatment of head and neck cancer in the last 15 years have been largely limited to those that impact on patient morbidity and quality of life, meanwhile, patient mortality statistics remain static. The application of new technologies in molecular biology and immunology may provide the head and neck oncologist with the tools to enhance patient survival.
